Suchergebnisse - (Subject:"Ritonavir")

PubPharm (2.062)

61

Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy

enthalten in: European journal of hospital pharmacy : science and practice | 2022

von Desideri, I. | Martinelli, C. | Ciuti, S. | +2

62

In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease

enthalten in: Molecules (Basel, Switzerland) | 2022

von Kashyap, P. | Thakur, M. | Singh, N. | +7

63

Can transcription factors in the intervertebral disc of lopinavir/ritonavir prevent degeneration in the nucleus pulposus by mediating the regulation of inflammation through signaling pathways?

enthalten in: European review for medical and pharmacological sciences | 2022

von Yilmaz, I. | Akalan, H. | Karaarslan, N. | +5

64

A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections

enthalten in: Antimicrobial agents and chemotherapy | 2022

von Mtshali, S. | Jacobs, B.

65

Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy : 48-week randomized, controlled, phase 3 non-inferiority TALENT study

enthalten in: The Journal of infection | 2022

von Su, B. | Yao, C. | Zhao, Q. | +37

66

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19 : final results

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2022

von Ader, F. | DisCoVeRy Study Group

67

Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

enthalten in: Obstetrics and gynecology | 2022

von Loza, A. | Farias, R. | Gavin, N. | +3

68

Emerging Therapies for COVID-19 : The Value of Information From More Clinical Trials

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2022

von Dijk, S. | Krijkamp, E. | Kunst, N. | +3

69

High-cited favorable studies for COVID-19 treatments ineffective in large trials

enthalten in: Journal of clinical epidemiology | 2022

von Ioannidis, J.

70

The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients : a single-center experience

enthalten in: Leukemia & lymphoma | 2022

von Bennett, R. | Chan, H. | Henderson, R. | +4